Table 3.
Multivariable Analysis Results for Events by 2 Years Post-HCT, Adjusted for Center Effects
| Variable | N | HR (99% CI) | P Value |
|---|---|---|---|
| Overall mortality | |||
| Main effect variable | .0002 | ||
| SibCNI, no NCHV infection | 1480 | 1.00 | |
| HaploCy with NCHV infection | 101 | 1.82 (1.18–2.80) | .0004 |
| SibCy with NCHV infection | 43 | 1.20 (0.61–2.34) | .4872 |
| SibCNI with NCHV infection | 89 | 1.38 (0.87–2.20) | .0705 |
| HaploCy, no NCHV infection | 628 | 1.31 (1.02–1.67) | .0057 |
| SibCy, no NCHV infection | 352 | 1.07 (0.75–1.51) | .6405 |
| Disease/cytogenetics/stage | <.0001 | ||
| Leukemia, favorable cytogenetics, early/intermediate | 68 | 1.00 | |
| Leukemia, intermediate/normal cytogenetics, early | 667 | 1.02 (0.58–1.80) | .9287 |
| Leukemia, poor cytogenetics, early | 434 | 0.99 (0.57–1.71) | .9604 |
| Leukemia, intermediate/normal cytogenetics, intermediate | 213 | 1.10 (0.63–1.92) | .6745 |
| Leukemia, poor cytogenetics, intermediate | 124 | 1.31 (0.72–2.36) | .2429 |
| Leukemia, any cytogenetics, advanced | 291 | 1.94 (1.09–3.45) | .0030 |
| MDS, very low/low | 307 | 0.91 (0.51–1.62) | .6594 |
| MDS intermediate | 229 | 1.57 (0.89–2.75) | .0400 |
| MDS high/very high | 162 | 2.04 (1.10–3.80) | .0029 |
| Missing | 198 | 1.33 (0.70–2.53) | .2529 |
| HCT-CI | .0007 | ||
| 0 | 679 | 1.00 | |
| 1–2 | 762 | 0.94 (0.66–1.34) | .6504 |
| 3–4 | 768 | 1.08 (0.77–1.53) | .5540 |
| 5+ | 484 | 1.30 (0.92–1.84) | .0543 |
| Age at HCT, yr | <.0001 | ||
| 0–20 | 234 | 1.00 | |
| 21–40 | 479 | 0.86 (0.60–1.25) | .3001 |
| 41–60 | 945 | 1.27 (0.90–1.79) | .0800 |
| >60 | 1035 | 1.61 (1.08–2.40) | .0019 |
| Acute GVHD grade II-IV | <.0001 | ||
| No | 1797 | 1.00 | |
| Yes | 896 | 1.54 (1.25–1.89) | |
| Main effect variable | .2551 | ||
| SibCNI, no NCHV infection | 1462 | 1.00 | |
| HaploCy with NCHV infection | 100 | 1.14 (0.69–1.86) | .5031 |
| SibCy with NCHV infection | 42 | 0.58 (0.24–1.43) | .1222 |
| SibCNI with NCHV infection | 87 | 0.90 (0.50–1.63) | .6434 |
| HaploCy, no NCHV infection | 617 | 1.14 (0.89–1.47) | .1697 |
| SibCy, no NCHV infection | 348 | 1.17 (0.82–1.67) | .2664 |
| Disease/cytogenetics/stage | <.0001 | ||
| Leukemia, favorable cytogenetics, early/intermediate | 67 | 1.00 | |
| Leukemia, intermediate/normal cytogenetics, early | 658 | 0.59 (0.34–1.05) | .0180 |
| Leukemia, poor cytogenetics, early | 430 | 0.82 (0.46–1.46) | .3724 |
| Leukemia, intermediate/normal cytogenetics, intermediate | 208 | 0.86 (0.50–1.49) | .4855 |
| Leukemia, poor cytogenetics, intermediate | 124 | 1.16 (0.62–2.17) | .5502 |
| Leukemia, any cytogenetics, advanced | 289 | 1.80 (1.06–3.07) | .0043 |
| MDS, very low/low | 305 | 0.98 (0.57–1.68) | .9132 |
| MDS intermediate | 227 | 1.14 (0.63–2.06) | .5663 |
| MDS high/very high | 159 | 2.12 (1.19–3.80) | .0009 |
| Missing | 189 | 1.04 (0.58–1.88) | .8533 |
| Conditioning intensity | <.0001 | ||
| Myeloablative | 1417 | 1.00 | |
| RIC/NMA | 1239 | 1.51 (1.27–1.79) | |
| Time from diagnosis to HCT (≤ 4 months) | <.0001 | ||
| <6 mo | 325 | 1.00 | |
| 6 mo-1 yr | 149 | 0.72 (0.56–0.93) | .0008 |
| ≥1 yr | 145 | 0.47 (0.32–0.67) | <.0001 |
| Time from diagnosis to HCT (>4 months) | .2843 | ||
| <6 mo | 1339 | 1.00 | |
| 6 mo-1 yr | 637 | 1.05 (0.79–1.41) | .6460 |
| ≥1 yr | 680 | 0.88 (0.66–1.18) | .2661 |
| Acute GVHD grade II-IV | <.001 | ||
| No | 1812 | 1.00 | |
| Yes | 844 | 0.79 (0.68–0.92) | |
| NRM | |||
| Main effect variable | <.001 | ||
| SibCNI, no NCHV infection | 1473 | 1.00 | |
| HaploCy with NCHV infection | 103 | 3.21 (1.70–6.09) | <.0001 |
| SibCy with NCHV infection | 42 | 2.50 (1.02–6.09) | .0083 |
| SibCNI with NCHV infection | 88 | 2.75 (1.39–5.45) | .0001 |
| HaploCy, no NCHV infection | 634 | 1.46 (0.87–2.44) | .0579 |
| SibCy, no NCHV infection | 352 | 1.10 (0.56–2.17) | .7231 |
| Donor-recipient sex match | .0021 | ||
| Male-male | 927 | 1.00 | |
| Male-female | 616 | 0.85 (0.50–1.44) | .4153 |
| Female-male | 658 | 1.32 (0.72–2.43) | .2317 |
| Female-female | 491 | 1.89 (0.93–3.86) | .0212 |
| Age at HCT, yr | .0021 | ||
| 0–20 | 234 | 1.00 | |
| 21–40 | 477 | 0.85 (0.50–1.44) | .4153 |
| 41–60 | 946 | 1.32 (0.72–2.43) | .2317 |
| >60 | 1035 | 1.89 (0.93–3.86) | .0212 |
| Acute GVHD, grade II-IV | <.0001 | ||
| No | 1837 | 1.00 | |
| Yes | 855 | 2.67 (1.83–3.91) | |
| Chronic GVHD | |||
| Main effect variable | <.0001 | ||
| SibCNI, no NCHV infection | 1486 | 1.00 | |
| HaploCy with NCHV infection | 104 | 0.81 (0.49–1.36) | .3035 |
| SibCy with NCHV infection | 43 | 0.73 (0.30–1.78) | .3689 |
| SibCNI with NCHV infection | 90 | 0.71 (0.45–1.10) | .0419 |
| HaploCy, no NCHV infection | 644 | 0.58 (0.44–0.78) | <.0001 |
| SibCy, no NCHV infection | 354 | 0.58 (0.38–0.87) | .0005 |
| Graft type | <.0001 | ||
| Bone marrow | 635 | 1.00 | |
| Peripheral blood | 2086 | 2.26 (1.69–3.02) | |
| Donor-recipient sex match | .0006 | ||
| Male-male | 936 | 1.00 | |
| Male-female | 621 | 1.01 (0.82–1.25) | .9195 |
| Female-male | 669 | 1.26 (1.03–1.55) | .0027 |
| Female-female | 495 | 1.24 (1.00–1.54) | .0084 |
| Number of viral infections (any) by day 180 | .0063 | ||
| None | 1545 | 1.00 | |
| 1 | 699 | 1.16 (0.96–1.40) | .0412 |
| 2 | 312 | 1.16 (0.90–1.51) | .1378 |
| 3+ | 165 | 1.54 (1.06–2.25) | .0032 |
| Acute GVHD, grade II-IV | .0018 | ||
| No | 1817 | 1.00 | |
| Yes | 904 | 1.27 (1.04–1.56) | |